Complete Response Letter

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

Aquestive Therapeutics faces securities fraud lawsuit after FDA rejected Anaphylm drug, contradicting management's prior "on track" statements; $AQST stock fell 37%.

Aldeyra Therapeutics stock plunged 71% after FDA rejected its reproxalap dry eye drug, prompting a securities investigation by Rosen Law Firm.

FDA rejects Disc Medicine's bitopertin drug, triggering 22% stock decline and securities investigation into potential investor losses.

FDA rejects Corcept's lead drug candidate, triggering 50% stock plunge and securities class action lawsuit. Lead plaintiff deadline set for April 21, 2026.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant. Stock crashed 50% following misleading investor claims about approval prospects.

$AQST plummets 37% after FDA rejects Anaphylm application. Investors sue over alleged misleading statements about approval prospects.

$CORT stock plummets 50% after FDA rejects lead drug relacorilant; class action targets alleged disclosure failures with lead plaintiff deadline April 21, 2026.

Johnson Fistel investigates Corcept Therapeutics ($COPT) for securities violations after FDA rejected relacorilant application, triggering 50% stock decline.

Corcept Therapeutics faces securities class action over allegedly misleading statements about relacorilant's FDA approval prospects, triggering 50% stock plunge and $3.6B market cap loss.

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.

Portnoy Law Firm sues Corcept Therapeutics over alleged misrepresentations about drug candidate relacorilant, following FDA rejection that caused stock to plummet 50%.

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.

Pomerantz Law Firm investigates Pharming Group after FDA rejects pediatric drug application, causing 17% stock decline. Inquiry focuses on whether regulatory risks were adequately disclosed to investors.